Senotherapeutics: encouraging results in mice, but not yet clinical proof

A synthesis of 26 experimental studies

The researchers compiled 26 studies involving mouse models: 15 focused on osteoarthritis, 6 on osteoporosis and 5 on sarcopenia. Their aim was to examine the effects of senotherapeutics on tissue structure and function, as well as the associated molecular mechanisms.

The literature search covered MEDLINE, Scopus and Web of Science, following PRISMA guidelines. The authors state that they assessed methodological quality using the SYRCLE RoB tool, which addresses the risk of bias in animal studies. However, the available abstract does not specify the results of this assessment, the numbers of animals or the duration of the experiments.

Targeting senescence, not demonstrating rejuvenation

The mechanism studied is cellular senescence. According to the abstract, it contributes to age-related tissue deterioration through functional changes and a pro-inflammatory environment. Senotherapeutics aim to selectively eliminate senescent cells or limit their harmful effects.

Overall, the studies reviewed report reduced inflammation and improvements in the musculoskeletal parameters assessed. These observations support the experimental interest in this biological target. They demonstrate neither overall rejuvenation nor an improvement in human health.

Results too varied to guide practice

The authors highlight the heterogeneity of the animal models, treatment protocols and outcome measures. Pooling these experiments therefore does not justify treating all senotherapeutics as equivalent. The abstract provides no effect size to quantify the reported benefit.

Nor does it detail the interventions, their comparators or their adverse effects. This review therefore cannot guide your choice of a product, dose or strategy to preserve your muscles, bones or joints. The authors call for further research to clarify the mechanisms and prepare for a possible clinical application.

What we can take away

These results justify further research into senotherapeutics, not adopting them to prevent age-related musculoskeletal disorders.